GSK-backed ViiV's Cabenuva shows viral suppression advantage over daily HIV therapy in trial

GSK-backed ViiV reported success in its Phase IIIb CROWN trial for long-acting Cabenuva in HIV patients with unsuppressed virus. The study demonstrated better viral suppression compared to standard daily oral therapy, potentially benefiting patients who struggle with adherence to pills.